SOURCE: Cyclodextrin Technologies Development, Inc.

Cyclodextrin Technologies Development, Inc.

January 31, 2011 14:21 ET

CTD Holdings, Inc. Adopts Revised Corporate Structure

ALACHUA, FL--(Marketwire - January 31, 2011) - CTD Holdings, Inc. (OTCQB: CTDH) (PINKSHEETS: CTDH) (OTCBB: CTDH) (FRANKFURT: CDJ) announces that the board of directors has unanimously approved the company's new corporate structure. Three additional separate, but wholly owned, subsidiaries have been created to address emerging target markets for the company's cyclodextrin-based technologies. With a more focused operational team, the new business divisions will each be able to apply their unique cyclodextrin expertise, addressing market changes and opportunities within their respective markets.

The structure of CTD Holdings Inc. now consists of the following four units:

Cyclodextrin Technologies Development, Inc. (CTD) (http://cyclodex.com/) -- This is the original business and is responsible for the marketing and sale of cyclodextrin fine chemicals in amounts less than 10 kg per order. CTD has the world's largest catalog of cyclodextrins and cyclodextrin complexes, which currently account for 95% of company revenue.

NanoSonic Products, Inc. (NSP) -- This unit will be the manufacturer of bulk Trappsol® and Aquaplex® products. Using proprietary methods and pulse drying technology, NSP will make up to multi-metric ton quantities of the company's Aquaplex® cyclodextrin complexes. NSP will also be the vendor for bulk quantities of Trappsol® cyclodextrins and cyclodextrin derivatives.

Sphingo Biotechnology, Inc. (SBI) -- SBI is responsible for the development and marketing of Trappsol® and Aquaplex® cyclodextrins as Active Pharmaceutical Ingredients (APIs). The division grows out of the requirement for more rigorous characterization of cyclodextrins to allow them to be used as APIs in the treatment of diseases associated with lipid metabolism defects, especially cholesterol and sphingolipids. Recently, Trappsol® Cyclo™ received orphan drug designation for the treatment of Niemann Pick type C (NPC) disease from the US FDA. SBI will initiate and fund research exploring the application of its Trappsol® Cyclo™ and other API Grade cyclodextrins to treat disease.

Ferrazo Environmental Technologies, Inc. (FET) -- Ferrazo-2B has been accepted as very safe and effective in the disbursement and cleanup of oil spills and other water insoluble environmental hazards. Ferrazo-2B is the company's first product and is currently in the final stages of EPA review for listing on their National Contingency Plan (NCP) product list.

All four CTD Holdings' subsidiaries will operate within their well-defined market sectors, with specific operational tasks and resources as dictated by the overall strategic plan. These streamlined, independent business units will now be able to better focus on the customers' needs and the demands of their respective markets, thereby adding to the overall profitability and growth of the holding company, CTD Holdings, Inc.

Our "Safe Harbor Statement" governs this news release. Please visit http://www.cyclodex.com/Safe-Harbor-Statement.html.

Contact Information